Please ensure Javascript is enabled for purposes of website accessibility

Why DBV Technologies SA Plummeted and Aimmune Therapeutics Inc Skyrocketed Today

By Brian Orelli, PhD - Oct 23, 2017 at 1:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One biotech's phase 3 failure benefits its competitor.

What happened

DBV Technologies (DBVT -6.28%) is down 45% at 12:48 p.m. EDT after announcing that its peanut allergy treatment, Viaskin Peanut, failed -- albeit not by much -- a phase 3 trial. The results caused Aimmune Therapeutics (AIMT), which has a peanut allergy treatment of its own, to shoot up 35%.

So what

In the phase 3 trial called PEPITES, 35.3% of patients responded to Viaskin Peanut after 12 months of treatment compared to 13.6% of patients who received placebo. While the 21.7% difference in response rate was substantial, the trial was set up so that it would only pass if the lower end of the 95% confidence interval was above 15%. Unfortunately, the 95% confidence interval -- a statistical measurement of where the difference in response rate would likely read out if the trial was repeated multiple times -- was 12.4% to 29.8%, just missing the 15% threshold.

DBV Technologies noted that the secondary endpoint, the cumulative reactive dose, which measures the amount of peanut protein a patient can have before reacting, showed patients who took Viaskin Peanut tolerated an average of 900 mg of peanut protein compared to 360 mg for patients who received placebo. Unfortunately, the Food and Drug Administration generally doesn't care about secondary endpoints in trials that don't pass the primary endpoint.

Nevertheless, DBV Technologies plans to continue with its application to the FDA. Data from a second phase 3 trial, REALISE, testing Viaskin Peanut in children treated for six months, is scheduled to be released next month.

Boy with hand extended refusing a bowl of peanuts

Image source: Getty Images.

Aimmune Therapeutics' peanut allergy treatment, AR101, isn't too far behind Viaskin Peanut with data from Aimmune's phase 3 PALISADE trial due to be reported in the first quarter of next year. Aimmune Therapeutics is also running a second phase 3 trial, called ARTEMIS, in children and adolescents, although that trial only started a few months ago.

Now what

Positive data from REALISE would strengthen DBV Technologies' FDA application, but history shows it's hard to get past the agency batting .500. That being said, the FDA is arguably more lenient than it has been in the past, so it makes sense for DBV to roll the dice and submit a marketing application.

DBV Technologies' failure is certainly good news for Aimmune Therapeutics, which deserves to be up today, but the just-missed-it failure should also be a reminder that biotech is risky and drugs can be derailed for statistical reasons even when the drug otherwise appears to be working.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DBV Technologies S.A. Stock Quote
DBV Technologies S.A.
DBVT
$2.39 (-6.28%) $0.16
Aimmune Therapeutics, Inc. Stock Quote
Aimmune Therapeutics, Inc.
AIMT

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.